Assessment of Irisin, Adiponectin and Leptin Levels in Patients with Schizophrenia

Author(s): Gamze Erzin* , Canan Topcuoglu , Vahap O. Kotan , Senol Bayram , Kostas Fountoulakis .

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets

Volume 18 , Issue 2 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Background: The patients with schizophrenia are at increased risk for problems regarding metabolic parameters due to their lifestyle and antipsychotic treatment.

Objective: In this study, we aimed to evaluate the levels of adiponectin, leptin, irisin in patients with schizophrenia who were nondiabetic, nonobese and under antipsychotic treatment.

Method: 5 ml sample of venous blood was collected from each participant. Blood cells were separated from the serum. The serum samples were stored in a -80°C freezer. Biochemical analyses were performed on these samples. Adiponectin, leptin and irisin levels were measured by Enzyme Linked Immunosorbent Assay method.

Results: The study included 88 subjects. Of them, 44 were patients with schizophrenia and 44 were healthy controls. There were no statistically significant results when the c-reactive protein, adiponectin, leptin and irisin levels were compared between the schizophrenia and the control group (p>0.05).

Conclusion: In our study, adiponectin, leptin and irisin levels in patients with schizophrenia did not present a statistically significant difference from healthy controls. Therefore, there is a need for studies including more participants to investigate the level of irisin in patients with schizophrenia.

Keywords: Adipokine, adiponectin, antipsychotics, irisin, leptin, metabolic syndrome, schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [163 - 169]
Pages: 7
DOI: 10.2174/1871530318666171207142901
Price: $58

Article Metrics

PDF: 15
PRC: 1